Tenaya Therapeutics, Inc.

Tenaya Therapeutics announced the appointment of Eric Hyllengren as its new Chief Financial Officer, effective July 13, 2026. Mr. Hyllengren brings over two decades of experience in biotechnology finance, capital markets, and corporate strategy, having previously served as CFO at Zura Bio and Atara Biotherapeutics. In his new role, he will oversee financial strategy, capital allocation, investor relations, and corporate development. Concurrently, Hiro Higa, Senior Vice President, Finance, will retire in the third quarter of 2026 but will remain as a consultant to ensure a smooth transition.

Tenaya Therapeutics reported positive interim safety and efficacy data from its MyPEAK-1 Phase 1b/2 clinical trial of TN-201 for MYBPC3-associated hypertrophic cardiomyopathy (HCM). All evaluable patients demonstrated improvements in multiple clinical parameters, including echocardiographic measures of hypertrophy and symptom burden, with higher doses showing earlier and more substantial changes. Additionally, TN-201 received PRIME designation from the EMA and was accepted into the FDA's Rare Disease Evidence Principles process for pediatric HCM.

Tenaya Therapeutics announced it will report new interim data from Cohort 1 and Cohort 2 of its MyPEAK™-1 Phase 1b/2 trial for TN-201 gene therapy on Wednesday, June 3, 2026. The data, concerning adults with MYBPC3-associated hypertrophic cardiomyopathy (HCM), will be reviewed during a live webcast. TN-201, designed to address the underlying genetic cause of HCM, has received Fast Track, Orphan Drug, and Rare Pediatric Drug Designations from the U.S. FDA, and orphan medicinal product status from the European Commission.

Tenaya Therapeutics, Inc. stockholders approved the Amended and Restated 2021 Equity Incentive Plan at the Annual Meeting on May 27, 2026. This plan includes a one-time increase of 6,509,966 shares (approximately 3% of outstanding shares) reserved for issuance and modifies the annual evergreen provision. Additionally, stockholders elected three Class II Directors and ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.

Tenaya Therapeutics, Inc. announced that its executive team will participate in the upcoming Jefferies Global Healthcare Conference from June 2-4, 2026, in New York. Faraz Ali, CEO, is scheduled to deliver a company presentation on Thursday, June 4, 2026, at 3:10 p.m. ET. A live webcast and an archived replay will be available on the company's website.

Tenaya Therapeutics presented positive interim data from its RIDGE-1 Phase 1b/2 clinical trial of TN-401 gene therapy for arrhythmogenic right ventricular cardiomyopathy (ARVC). All six patients treated with TN-401 showed meaningful reductions (mean 64%) in premature ventricular contractions (PVCs), and the therapy was well tolerated at both dose levels. Post-dose biopsies confirmed TN-401 activity in heart muscle cells, and the European Medicines Agency (EMA) granted TN-401 PRIority MEdicine (PRIME) designation.

Tenaya Therapeutics reported a reduced net loss of $19.3 million for Q1 2026, down from $26.9 million in Q1 2025, driven by lower operating expenses and the initiation of collaboration revenue. The company also entered a significant collaboration agreement with Alnylam Pharmaceuticals, Inc., which includes an upfront platform access fee of up to $10.0 million and potential future milestone payments of up to $1.1 billion. Management believes existing cash and cash equivalents of $80.9 million are sufficient to fund operations for at least the next twelve months.

Tenaya Therapeutics reported a reduced net loss of $19.3 million for Q1 2026, down from $26.9 million in Q1 2025, with R&D and G&A expenses also decreasing. The company announced upcoming presentations of one-year data for TN-401 and initial data for TN-201 gene therapies, alongside positive preclinical data for TN-301 in Duchenne muscular dystrophy. A new research collaboration with Alnylam Pharmaceuticals, including a $10.0 million upfront payment, extends the cash runway into the second half of 2027.

Tenaya Therapeutics announced multiple abstract acceptances for the ASGCT Annual Meeting in May 2026. The highlight is a late-breaking oral presentation of new clinical data from both dose cohorts of the RIDGE-1 Phase 1b/2 trial for TN-401, a gene therapy for PKP2-associated ARVC. This presentation will include one-year Cohort 1 results and early Cohort 2 data on safety, biopsy, and efficacy. Additionally, the company will present two posters on parental perceptions of gene therapy for children with cardiomyopathies and research on TN-501 for PLN-R14del-associated DCM. A webcast conference call is planned to discuss the TN-401 data.